



MAYNE PHARMA LAUNCHES GENERIC QUARTETTE® IN THE US, ANOTHER WOMEN'S HEALTH PRODUCT

27 Mar 2018, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of an authorised generic of Quartette® (levonorgestrel and ethinyl estradiol tablets, 0.15mg/0.02mg; 0.15mg/0.025mg; 0.15mg/0.03mg and ethinyl estradiol tablets, 0.01mg) in the United States. Quartette is an oral contraceptive indicated for the prevention of pregnancy.

Mayne Pharma's CEO Scott Richards said, "Generic Quartette adds to our women's health portfolio of 22 marketed products including oral contraceptives, hormone replacement therapy and breast cancer products. Mayne Pharma is the second largest supplier of oral contraceptives in the US and continues to invest in growing its pipeline of women's health products with high value, complex formulations such as generic NuvaRing® an intra vaginal hormonal contraceptive delivery device which was recently accepted for filing by the US FDA."

Mayne Pharma directly markets more than 55 products and has a growing pipeline of approximately 30 drug products targeting US markets with IQVIA sales greater than US\$5 billion. According to IQVIA, US brand and generic sales for this product were approximately US\$10 million for the 12 months ending 31 January 2018.

For further information contact:

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in formulation complex oral dose forms including highly potent compounds, controlled substances, modified release products and inherently unstable compounds.

Quartette® is a registered trademark of Teva Women's Health, LLC and NuvaRing® is a registered trademark of N.V. Organon Corporation.